GlaxoSmithKline PLC (GSK)

43.88
NYSE : Health Care
Prev Close 43.60
Day Low/High 43.77 / 43.98
52 Wk Low/High 37.24 / 45.49
Avg Volume 3.49M
Exchange NYSE
Shares Outstanding 2.44B
Market Cap 106.18B
EPS 5.20
P/E Ratio 25.06
Div & Yield 2.00 (4.60%)

Latest News

Celgene, Jounce Therapeutics in Early Cancer Immunotherapy Development Pact

Celgene, Jounce Therapeutics in Early Cancer Immunotherapy Development Pact

Celgene continues to sprinkle cash around the biotech sector, tying up with smaller companies for first-dibs access to potentially valuable drugs and technologies.

Novartis Second-Quarter Earnings, Revenue Fall Less Than Forecast

Novartis Second-Quarter Earnings, Revenue Fall Less Than Forecast

The pharmaceuticals company, led by CEO Joe Jiminez, had its first full quarter of generic competition for its Gleevec cancer drug.

SoftBank Spurs Post-Brexit U.K. M&A Hopes With ARM Bid

SoftBank Spurs Post-Brexit U.K. M&A Hopes With ARM Bid

As a bombed-out pound leaves British assets at a discount, who will be next in the post-Brexit M&A binge?

Grab a Bit of Britain With FTSE 100 ETF

Grab a Bit of Britain With FTSE 100 ETF

The U.K. isn't going anywhere Brexit vote notwithstanding, and here's a way to get on the most business-friendly state across the pond.

European Markets Mixed After Bank of England Keeps Rate Steady

European Markets Mixed After Bank of England Keeps Rate Steady

Bank of England defies market expectations and keeps rate at 0.5%; expects easing in August.

Glaxo Gains Jefferies Upgrade on Stronger HIV Drugs Performance, Currency Benefits

Glaxo Gains Jefferies Upgrade on Stronger HIV Drugs Performance, Currency Benefits

Shares in the U.K.'s leading pharmaceuticals company have risen about 20% since the June 23 Brexit vote.

European Markets Pare Gains After Bank of England Keeps Rate Steady

European Markets Pare Gains After Bank of England Keeps Rate Steady

Bank of England defies market expectations and keeps rate at 0.5%

European Stocks Rise Ahead of Expected Bank of England Rate Cut

European Stocks Rise Ahead of Expected Bank of England Rate Cut

UniCredit rises after the bank's chairman says asset sales won't address ECB capital demands, while BASF gains in Frankfurt on talk of the transfer of an agricultural unit to Monsanto.

3 Vaccine Manufacturers That Investors Should Consider for Their Portfolios

3 Vaccine Manufacturers That Investors Should Consider for Their Portfolios

Pfizer, Merck and GlaxoSmithKline are all producing blockbuster vaccines and have others in their pipelines.

European Stocks: What's Your Pain Tolerance?

If you think the best thing to do post-Brexit is buy more, here are 4 to consider.

'Shark Tank's' Kevin O'Leary Finds 'The Opportunity of a Lifetime'

'Shark Tank's' Kevin O'Leary Finds 'The Opportunity of a Lifetime'

'Shark Tank's' Kevin O'Leary joined CNBC's 'Fast Money Halftime Report' to talk about the selloff in European Markets and the companies he bought on his European shopping spree.

Shire and Glaxo Offer Prescription to London's Woes

Shire and Glaxo Offer Prescription to London's Woes

U.K.-listed drugs companies are likely to remain in rude health even if Britain stumbles post Brexit.

GlaxoSmithKline (GSK) Flagged As Today's Pre-Market Laggard

GlaxoSmithKline (GSK) Flagged As Today's Pre-Market Laggard

Trade-Ideas LLC identified GlaxoSmithKline (GSK) as a pre-market laggard candidate

GlaxoSmithKline Has No Cure for Sideways Action

GSK has been largely stuck between $44 on the upside and $37 on the downside for the past 12 months.

Sell These 5 U.K. Stocks Now Before the Brexit Vote

Sell These 5 U.K. Stocks Now Before the Brexit Vote

Regardless of which way the vote goes, these five companies based across the pond are teetering on the edge of big potential sell signals.

What To Hold: 3 Hold-Rated Dividend Stocks SEAS, SIR, GSK

What To Hold: 3 Hold-Rated Dividend Stocks SEAS, SIR, GSK

These 3 dividend stocks are rated a Hold by TheStreet

GlaxoSmithKline (GSK) Leads The Pack In Pre-Market Activity

GlaxoSmithKline (GSK) Leads The Pack In Pre-Market Activity

Trade-Ideas LLC identified GlaxoSmithKline (GSK) as a pre-market leader candidate

The Charts Do Not Look Pretty for These 3 Dividend Stocks Under Brexit Pressure

The Charts Do Not Look Pretty for These 3 Dividend Stocks Under Brexit Pressure

These high-yield dividend stocks are under pressure from the possibility of Britain leaving the European Union. While some may see this as an opportunity, the technical analysis says otherwise.

3 High-Yield Dividend Stocks You Should Buy as Brexit Fears Swirl

3 High-Yield Dividend Stocks You Should Buy as Brexit Fears Swirl

Brexit fears are creating opportunities to buy these three established high-dividend businesses at a discount.

Perrigo Rises Further as Takeover Rumor Swirls

Perrigo Rises Further as Takeover Rumor Swirls

With no outright denial of the story to kill it, Perrigo's share rose further in Tel Aviv overnight on a day-old rumor of a $20 billion takeover deal.

GlaxoSmithKline (GSK) Stock Lower as Chairman of Vaccines Retires

GlaxoSmithKline (GSK) Stock Lower as Chairman of Vaccines Retires

GlaxoSmithKline (GSK) stock is retreating this afternoon as its chairman of vaccines will retire next year.

3 Stocks Pulling The Health Care Sector Downward

3 Stocks Pulling The Health Care Sector Downward

TheStreet highlights 3 stocks pushing the health care sector lower today.

Sell Alert: These 5 Stocks Look Toxic Right Now

Sell Alert: These 5 Stocks Look Toxic Right Now

It's time to unload these toxic stocks from your portfolio.

European, Asian Stock Benchmarks Rise Before Payrolls

European, Asian Stock Benchmarks Rise Before Payrolls

Final purchasing managers' data for the eurozone come in better than initial estimates.

Nasdaq’s Overbought Territory to Loom Larger

It’s already in the overbought territory, but by Monday it’s expected to be maximum overbought.

Regulus Expands Clinical Trial Collaboration With GSK

Regulus Expands Clinical Trial Collaboration With GSK

- Phase II Study Evaluating the Combination of RG-101 and GSK's Long-Acting Parenteral (LAP) Formulation of GSK2878175 as a potential single-visit cure to begin Q4 2016